SCHEMBL25548932

SCHEMBL25548932

COC(C)[C@H](NC(=O)c1ccc2ccccc2c1OCc1ccc(C(F)(F)F)cc1)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 2/20 0.64
ADAMTS4 O75173 1/20 0.41
MMP13 P45452 1/20 0.41
MRGPRX4 Q96LA9 2/20 0.40
PYGL P06737 2/20 0.40
CYP2C9 P11712 2/20 0.40
MME P08473 1/20 0.40
ACE P12821 1/20 0.40
CPA1 P15085 1/20 0.40
ACE2 Q9BYF1 1/20 0.40
LMNA P02545 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KIFC1 Q9BW19 1/20 0.39
PPARD Q03181 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25192219 1.00 CXCR2 (0.64) CXCR2ADAMTS4MMP13MRGPRX4PYGL
SCHEMBL25549099 0.92 CXCR2 (0.63) CXCR2ADAMTS4MMP13MRGPRX4PYGL
SCHEMBL23460776 0.92 CXCR2 (0.63) CXCR2ADAMTS4MMP13MRGPRX4PYGL
SCHEMBL23460775 0.92 CXCR2 (0.63) CXCR2ADAMTS4MMP13MRGPRX4PYGL
SCHEMBL1598964 0.92 CXCR2 (0.64) CXCR2ADAMTS4MMP13MRGPRX4MME
SCHEMBL485430 0.92 CXCR2 (0.64) CXCR2ADAMTS4MMP13MRGPRX4MME
SCHEMBL23460868 0.91 CXCR2 (0.62) CXCR2ADAMTS4MMP13MRGPRX4PYGL
SCHEMBL23461213 0.91 CXCR2 (0.62) CXCR2ADAMTS4MMP13MRGPRX4PYGL
SCHEMBL23460867 0.91 CXCR2 (0.62) CXCR2ADAMTS4MMP13MRGPRX4PYGL
SCHEMBL25548930 0.91 CXCR2 (0.62) CXCR2ADAMTS4MMP13MRGPRX4PYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885ADAMTS4 4215/4885MMP13 3159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.